Richard Law
Stock Analyst at Goldman Sachs
(2.42)
# 1,299
Out of 4,479 analysts
48
Total ratings
21.74%
Success rate
1.48%
Average return
Main Sectors:
Top Industries:
13 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRDN Viridian Therapeutics | Initiates: Buy | $23 | $13.21 | +74.11% | 1 | Jun 6, 2024 | |
| MLYS Mineralys Therapeutics | Initiates: Buy | $30 | $12.17 | +146.51% | 5 | Apr 2, 2024 | |
| OLMA Olema Pharmaceuticals | Initiates: Buy | $24 | $11.14 | +115.44% | 4 | Apr 2, 2024 | |
| RCKT Rocket Pharmaceuticals | Initiates: Neutral | $39 | $20.66 | +88.77% | 1 | Apr 2, 2024 | |
| MLTX MoonLake Immunotherapeutics | Initiates: Neutral | $62 | $41.80 | +48.33% | 1 | Apr 2, 2024 | |
| GLUE Monte Rosa Therapeutics | Reiterates: Neutral | $11 | $3.94 | +179.19% | 4 | Aug 11, 2023 | |
| VERV Verve Therapeutics | Reiterates: Neutral | $31 | $4.98 | +522.49% | 2 | Aug 11, 2023 | |
| BEAM Beam Therapeutics | Maintains: Neutral | $46 → $47 | $23.05 | +103.90% | 3 | Aug 9, 2023 | |
| CRSP CRISPR Therapeutics AG | Maintains: Neutral | $62 → $63 | $53.95 | +16.77% | 6 | Aug 8, 2023 | |
| KYMR Kymera Therapeutics | Maintains: Neutral | $36 → $37 | $30.95 | +19.55% | 8 | Aug 4, 2023 | |
| NTLA Intellia Therapeutics | Reiterates: Outperform | $76 | $22.47 | +238.23% | 6 | Jun 13, 2023 | |
| EDIT Editas Medicine | Maintains: Neutral | $15 → $14 | $4.61 | +203.69% | 3 | May 8, 2023 | |
| ARVN Arvinas | Reiterates: Outperform | $61 | $25.98 | +134.80% | 4 | May 8, 2023 |
Viridian Therapeutics
Jun 6, 2024
Initiates: Buy
Price Target: $23
Current: $13.21
Upside: +74.11%
Mineralys Therapeutics
Apr 2, 2024
Initiates: Buy
Price Target: $30
Current: $12.17
Upside: +146.51%
Olema Pharmaceuticals
Apr 2, 2024
Initiates: Buy
Price Target: $24
Current: $11.14
Upside: +115.44%
Rocket Pharmaceuticals
Apr 2, 2024
Initiates: Neutral
Price Target: $39
Current: $20.66
Upside: +88.77%
MoonLake Immunotherapeutics
Apr 2, 2024
Initiates: Neutral
Price Target: $62
Current: $41.80
Upside: +48.33%
Monte Rosa Therapeutics
Aug 11, 2023
Reiterates: Neutral
Price Target: $11
Current: $3.94
Upside: +179.19%
Verve Therapeutics
Aug 11, 2023
Reiterates: Neutral
Price Target: $31
Current: $4.98
Upside: +522.49%
Beam Therapeutics
Aug 9, 2023
Maintains: Neutral
Price Target: $46 → $47
Current: $23.05
Upside: +103.90%
CRISPR Therapeutics AG
Aug 8, 2023
Maintains: Neutral
Price Target: $62 → $63
Current: $53.95
Upside: +16.77%
Kymera Therapeutics
Aug 4, 2023
Maintains: Neutral
Price Target: $36 → $37
Current: $30.95
Upside: +19.55%
Intellia Therapeutics
Jun 13, 2023
Reiterates: Outperform
Price Target: $76
Current: $22.47
Upside: +238.23%
Editas Medicine
May 8, 2023
Maintains: Neutral
Price Target: $15 → $14
Current: $4.61
Upside: +203.69%
Arvinas
May 8, 2023
Reiterates: Outperform
Price Target: $61
Current: $25.98
Upside: +134.80%